English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/214802
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions

Other TitlesSARS-CoV-2 in Mast Cell Disorders
AuthorsValent, Peter; Akin, Cem; Bonadonna, Patrizia; Brockow, Knut; Niedoszytko, Marek; Nedoszytko, Boguslaw; Butterfield, Joseph H.; Álvarez-Twose, Iván; Sotlar, Karl; Schwaab, Juliana; Jawhar, Mohamad; Reiter, Andreas; Castells, Mariana; Sperr, Wolfgang R.; Kluin-Nelemans, Hanneke C.; Hermine, Olivier; Gotlib, Jason; Zanotti, Roberta; Broesby-Olsen, Sigurd; Horny, Hans-Peter; Triggiani, Massimo; Siebenhaar, Frank; Orfao, Alberto ; Metcalfe, Dean D.; Arock, Michel; Hartmann, Karin
KeywordsMast Cells
Mastocytosis
Tryptase
KITD816V
Coronavirus
COVID-19
SARS-CoV-2
Mast Cell Activation Syndrome
Issue Date17-Jun-2020
PublisherElsevier
CitationJournal of Allergy and Clinical Immunology 146(2): 300-306 (2020)
AbstractThe COVID-19 (SARS-CoV-2) pandemic has massively distorted our health care systems and caused catastrophic consequences in our affected communities. The number of victims continues to increase and patients at risk can only be protected to a degree, since the virulent state may be asymptomatic. Risk factors concerning COVID-19-induced morbidity and mortality include advanced age, an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and cancer treated with chemotherapy. Here within, we discuss the risk and impact of COVID-19 in patients with mastocytosis and mast cell activation syndromes. As no published data are yet available, expert opinions are, by necessity, based on case experience and reports from patients. Whereas the overall risk to acquire the SARS-CoV-2 virus may not be elevated in mast cell disease, certain conditions may increase the risk of infected patients to develop severe COVID-19. These factors include certain co-morbidities, mast cell activation-related events affecting the cardiovascular or bronchopulmonary system and chemotherapy or immunosuppressive drugs. Therefore, such treatments should be carefully evaluated on a case-by-case basis during a COVID-19 infection. By contrast, other therapies, such as anti-mediator-type drugs, venom immunotherapy, or vitamin D, should be continued. Overall, patients with mast cell disorders should follow the general and local guidelines in the COVID-19 pandemic and advice from their medical provider.
Publisher version (URL)https://doi.org/10.1016/j.jaci.2020.06.009
URIhttp://hdl.handle.net/10261/214802
DOIhttp://dx.doi.org/10.1016/j.jaci.2020.06.009
ISSN0091-6749
E-ISSN1097-6825
Appears in Collections:(IBMCC) Artículos
(VICYT) Colección Especial COVID-19
Files in This Item:
File Description SizeFormat 
riskecpeopin.pdf204,04 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.